Frans Janssens

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines
    Frans Janssens
    Medicinal Chemistry Department, Johnson and Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica NV, Turnhoutseweg 30, B 2340 Beerse, Belgium
    J Med Chem 48:2154-66. 2005
  2. ncbi Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)
    Jean Francois Bonfanti
    Medicinal Chemistry Department, Johnson and Johnson Pharmaceutical Research and Development, Campus de Maigremont, BP 615, F 27106 Val de Reuil, France
    J Med Chem 51:875-96. 2008
  3. ncbi Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus
    Koen Andries
    Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
    Antiviral Res 60:209-19. 2003
  4. ncbi Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship
    Jean Francois Bonfanti
    Johnson and Johnson Pharmaceutical Research and Development, Medicinal Chemistry Department, Campus de Maigremont BP315, F 27106 Val de Reuil, France
    J Med Chem 50:4572-84. 2007

Collaborators

Detail Information

Publications4

  1. ncbi Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines
    Frans Janssens
    Medicinal Chemistry Department, Johnson and Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica NV, Turnhoutseweg 30, B 2340 Beerse, Belgium
    J Med Chem 48:2154-66. 2005
    ..Compound 3a has been selected for further clinical development, mainly for application in dermatology...
  2. ncbi Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)
    Jean Francois Bonfanti
    Medicinal Chemistry Department, Johnson and Johnson Pharmaceutical Research and Development, Campus de Maigremont, BP 615, F 27106 Val de Reuil, France
    J Med Chem 51:875-96. 2008
    ..This paper describes a molecular modeling study followed by a lead optimization program that led to the recovery of the initial potent antiviral activity and the selection of TMC353121 as a clinical candidate...
  3. ncbi Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus
    Koen Andries
    Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
    Antiviral Res 60:209-19. 2003
    ..JNJ 2408068 was also shown to inhibit the release of proinflammatory cytokines IL-6, IL-8 and Rantes from RSV-infected A549 cells...
  4. ncbi Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship
    Jean Francois Bonfanti
    Johnson and Johnson Pharmaceutical Research and Development, Medicinal Chemistry Department, Campus de Maigremont BP315, F 27106 Val de Reuil, France
    J Med Chem 50:4572-84. 2007
    ..We were able to identify new respiratory syncytial virus inhibitors with shorter half-lives in lung tissue...